Advanced Proteome Th (APTCF) 0.0470 $APTCF
TSX Venture Exchange Daily Bulletins
CNW Group - Mon May 30, 5:31PM CDT
TSX VENTURE COMPANIES
Advanced Proteome Announces Private Placement
Marketwired - Mon Apr 18, 8:30AM CDT
Advanced Proteome Therapeutics Corporation (TSX VENTURE: APC)(FRANKFURT: 0E8)
APC.VN: 0.040 (-0.010)
Advanced Proteome Therapeutics Corporation Embarks Upon a Major Antibody Initiative
Marketwire Canada - Fri Apr 15, 8:15AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC)(FRANKFURT: 0E8) announces that APC has invented a novel approach to a persistent problem in the field of antibody-drug conjugates (ADCs), one which ideally is able to site-selectively add virtually any drug to any IgG antibody (which provides most of the scaffolds for ADC formation). The approach is expected to yield products of high purity, which should improve clinical performance and provide numerous business opportunities for licensing and partnering in joint efforts. It is noteworthy that antibody therapeutics are estimated to reach yearly sales of nearly $125 Billion USD by the year 2020, highlighting the extraordinary growth that is anticipated in this market.
APC.VN: 0.040 (-0.010)
Advanced Proteome Therapeutics (APC) to Attend BIO-Europe Spring 2016 Partnering Conference
Marketwired - Thu Mar 24, 8:30AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) (FRANKFURT: 0E8) announces that APC will be attending the 10th Annual International Partnering Conference, at BIO-Europe, Spring 2016, April 4-6, in Stockholm, Sweden. This is Europe's largest partnering conference within the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies.
APC.VN: 0.040 (-0.010)
Colon Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbmf4p/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Pipeline Products for Colon Cancer - Overview - Pipeline Products for Colon Cancer - Comparative Analysis - Colon Cancer - Therapeutics under Development by Companies - Colon Cancer - Therapeutics under Investigation by Universities/Institutes - Colon Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colon Cancer - Products under Development by Companies - Colon Cancer - Products under Investigation by Universities/Institutes - Colon Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - ACF Pharmaceuticals, LLC - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aptose Biosciences Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bio-Path Holdings, Inc. - Biogazelle - Bioncotech Therapeutics S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - Carna Biosciences, Inc. - Celyad SA - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/pb...lon_cancer
ADRO: 12.66 (+0.42), AMBX: (), CLBS: 0.54 (unch), CANF: 2.95 (-0.02), APTO: 2.96 (+0.26), AVXL: 4.35 (-0.29), BPTH: 2.50 (+0.06), AZN: 29.64 (-0.21), CYAD: 57.00 (-1.47)
Advanced Proteome Therapeutics Corporation Attending JP Morgan Healthcare Conference Week January 10-14th, 2016
Marketwired - Mon Jan 04, 8:30AM CST
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) (FRANKFURT: 0E8) will be attending the Biotech Showcase Conference, held in San Francisco during the 34th Annual JP Morgan Healthcare Conference week, January 10th - 14th, 2016.
APC.VN: 0.040 (-0.010)
Advanced Proteome Therapeutics Updates Study of APC 101
Marketwired - Fri Dec 04, 6:44PM CST
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) (FRANKFURT: 0E8) is following up on its news release of April 29, 2015 that reported on testing of APC 101 in the 4T1 mouse model.
APC.VN: 0.040 (-0.010)
BUYINS.NET: APC SqueezeTrigger Price is $71.59. There is $824,407,200 That Short Sellers Still Need To Cover.
M2 - Wed Nov 04, 11:40AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring Advanced Proteome Therapeutics Corp (NYSE:APC) in real time and just received an alert that APC is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 11450100 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $71.59. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
APC: 55.18 (-0.04)
BUYINS.NET: APC SqueezeTrigger Price is $71.61. There is $831,162,759 That Short Sellers Still Need To Cover.
M2 - Thu Oct 22, 10:48AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Advanced Proteome Therapeutics Corp (NYSE:APC) in real time and just received an alert that APC is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 11450100 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $71.61. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
APC: 55.18 (-0.04)
Fibrosarcoma Pipeline Review, H2 2015 - 6 Companies & 9 Drug Profiles
M2 - Wed Sep 23, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j2h4np/fibrosarcoma) has announced the addition of the "Fibrosarcoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fibrosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advanced Proteome Therapeutics Corporation - Novartis AG - Plexxikon Inc. - Rigontec GmbH - Siena Biotech S.p.A. - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - APC-103 - DSR-6434 - everolimus - ImOl-100 - KRA-0008 - LK-3 - MAT-303 - PLX-7486 - SEN-461 For more information visit http://www.researchandmarkets.com/research/j2...brosarcoma
NVS: 81.39 (-0.22)
Colon Cancer Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Colon Cancer and Enlists all Their Major and Minor Projects
M2 - Fri Aug 14, 8:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6lqjnr/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Colon Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - AlphaVax, Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Apogenix GmbH - Aposense Ltd. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bavarian Nordic A/S - Bio-Path Holdings, Inc. - Bioncotech Therapeutics S.L. - Bionomics Limited - Carna Biosciences, Inc. - Celyad - Cold Genesys, Inc. For more information visit http://www.researchandmarkets.com/research/6l...lon_cancer
ADRO: 12.66 (+0.42), AVXL: 4.35 (-0.29), BPTH: 2.50 (+0.06), AMBX: (), AZN: 29.64 (-0.21), CYAD: 57.00 (-1.47)
Advanced Proteome Appoints Dr. Randal Chase to Its Board
Marketwired - Tue Jun 02, 8:04AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce the appointment of Dr. Randal Chase to its Board of Directors. Dr. Chase currently serves as Chairman of MediMabs, a privately held company, and is a member of the Board of Geovax Labs, Inc., a vaccine company trading on the OTCQX.
NVX: 16.19 (+0.07), APC.VN: 0.040 (-0.010)
Advanced Proteome Therapeutics Reports on Warrant Exercise
Marketwired - Tue May 19, 8:15AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to report that all of the 3,100,000 share purchase warrants that were issued under the Company's private placement that closed on November 5, 2013, having an expiry date of May 5, 2015, have been exercised by the holders to purchase 3,100,000 common shares of the Company at a price of CDN $0.15 per share, for proceeds to the Company of CDN $465,000.
APC.VN: 0.040 (-0.010)
Advanced Proteome Therapeutics' Lead Compound Inhibits Metastasis in Breast Cancer Tumor Model
Marketwired - Wed Apr 29, 11:47AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce that its current lead compound APC 101 successfully diminished the frequency of tumor metastasis in the 4T1 animal model.
APC.VN: 0.040 (-0.010)
Advanced Proteome Therapeutics Reports Successful Fusion Protein Initiative Resulting in APC 103 Which Retards Tumor Growth in an Animal Model
Marketwired - Mon Apr 27, 8:02AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce that its new fusion protein, APC 103, exhibited enhanced activity over the parent protein in retarding tumor growth in animal studies, comparable to APC 101 which has been the Company's principal point of focus to date.
APC.VN: 0.040 (-0.010)
TSX Venture Exchange Daily Bulletins
CNW Group - Mon May 30, 5:31PM CDT
TSX VENTURE COMPANIES
Advanced Proteome Announces Private Placement
Marketwired - Mon Apr 18, 8:30AM CDT
Advanced Proteome Therapeutics Corporation (TSX VENTURE: APC)(FRANKFURT: 0E8)
APC.VN: 0.040 (-0.010)
Advanced Proteome Therapeutics Corporation Embarks Upon a Major Antibody Initiative
Marketwire Canada - Fri Apr 15, 8:15AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC)(FRANKFURT: 0E8) announces that APC has invented a novel approach to a persistent problem in the field of antibody-drug conjugates (ADCs), one which ideally is able to site-selectively add virtually any drug to any IgG antibody (which provides most of the scaffolds for ADC formation). The approach is expected to yield products of high purity, which should improve clinical performance and provide numerous business opportunities for licensing and partnering in joint efforts. It is noteworthy that antibody therapeutics are estimated to reach yearly sales of nearly $125 Billion USD by the year 2020, highlighting the extraordinary growth that is anticipated in this market. APC.VN: 0.040 (-0.010)
Advanced Proteome Therapeutics (APC) to Attend BIO-Europe Spring 2016 Partnering Conference
Marketwired - Thu Mar 24, 8:30AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) announces that APC will be attending the 10th Annual International Partnering Conference, at BIO-Europe, Spring 2016, April 4-6, in Stockholm, Sweden. This is Europe's largest partnering conference within the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. APC.VN: 0.040 (-0.010)
Colon Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbmf4p/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Pipeline Products for Colon Cancer - Overview - Pipeline Products for Colon Cancer - Comparative Analysis - Colon Cancer - Therapeutics under Development by Companies - Colon Cancer - Therapeutics under Investigation by Universities/Institutes - Colon Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colon Cancer - Products under Development by Companies - Colon Cancer - Products under Investigation by Universities/Institutes - Colon Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - ACF Pharmaceuticals, LLC - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aptose Biosciences Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bio-Path Holdings, Inc. - Biogazelle - Bioncotech Therapeutics S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - Carna Biosciences, Inc. - Celyad SA - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/pb...lon_cancer
ADRO: 12.66 (+0.42), AMBX: (), CLBS: 0.54 (unch), CANF: 2.95 (-0.02), APTO: 2.96 (+0.26), AVXL: 4.35 (-0.29), BPTH: 2.50 (+0.06), AZN: 29.64 (-0.21), CYAD: 57.00 (-1.47)
Advanced Proteome Therapeutics Corporation Attending JP Morgan Healthcare Conference Week January 10-14th, 2016
Marketwired - Mon Jan 04, 8:30AM CST
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) will be attending the Biotech Showcase Conference, held in San Francisco during the 34th Annual JP Morgan Healthcare Conference week, January 10th - 14th, 2016. APC.VN: 0.040 (-0.010)
Advanced Proteome Therapeutics Updates Study of APC 101
Marketwired - Fri Dec 04, 6:44PM CST
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) is following up on its news release of April 29, 2015 that reported on testing of APC 101 in the 4T1 mouse model. APC.VN: 0.040 (-0.010)
BUYINS.NET: APC SqueezeTrigger Price is $71.59. There is $824,407,200 That Short Sellers Still Need To Cover.
M2 - Wed Nov 04, 11:40AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring Advanced Proteome Therapeutics Corp (NYSE:APC) in real time and just received an alert that APC is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 11450100 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $71.59. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
APC: 55.18 (-0.04)
BUYINS.NET: APC SqueezeTrigger Price is $71.61. There is $831,162,759 That Short Sellers Still Need To Cover.
M2 - Thu Oct 22, 10:48AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Advanced Proteome Therapeutics Corp (NYSE:APC) in real time and just received an alert that APC is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 11450100 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $71.61. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
APC: 55.18 (-0.04)
Fibrosarcoma Pipeline Review, H2 2015 - 6 Companies & 9 Drug Profiles
M2 - Wed Sep 23, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j2h4np/fibrosarcoma) has announced the addition of the "Fibrosarcoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fibrosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advanced Proteome Therapeutics Corporation - Novartis AG - Plexxikon Inc. - Rigontec GmbH - Siena Biotech S.p.A. - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - APC-103 - DSR-6434 - everolimus - ImOl-100 - KRA-0008 - LK-3 - MAT-303 - PLX-7486 - SEN-461 For more information visit http://www.researchandmarkets.com/research/j2...brosarcoma
NVS: 81.39 (-0.22)
Colon Cancer Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Colon Cancer and Enlists all Their Major and Minor Projects
M2 - Fri Aug 14, 8:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6lqjnr/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Colon Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - AlphaVax, Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Apogenix GmbH - Aposense Ltd. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bavarian Nordic A/S - Bio-Path Holdings, Inc. - Bioncotech Therapeutics S.L. - Bionomics Limited - Carna Biosciences, Inc. - Celyad - Cold Genesys, Inc. For more information visit http://www.researchandmarkets.com/research/6l...lon_cancer
ADRO: 12.66 (+0.42), AVXL: 4.35 (-0.29), BPTH: 2.50 (+0.06), AMBX: (), AZN: 29.64 (-0.21), CYAD: 57.00 (-1.47)
Advanced Proteome Appoints Dr. Randal Chase to Its Board
Marketwired - Tue Jun 02, 8:04AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce the appointment of Dr. Randal Chase to its Board of Directors. Dr. Chase currently serves as Chairman of MediMabs, a privately held company, and is a member of the Board of Geovax Labs, Inc., a vaccine company trading on the OTCQX. NVX: 16.19 (+0.07), APC.VN: 0.040 (-0.010)
Advanced Proteome Therapeutics Reports on Warrant Exercise
Marketwired - Tue May 19, 8:15AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to report that all of the 3,100,000 share purchase warrants that were issued under the Company's private placement that closed on November 5, 2013, having an expiry date of May 5, 2015, have been exercised by the holders to purchase 3,100,000 common shares of the Company at a price of CDN $0.15 per share, for proceeds to the Company of CDN $465,000. APC.VN: 0.040 (-0.010)
Advanced Proteome Therapeutics' Lead Compound Inhibits Metastasis in Breast Cancer Tumor Model
Marketwired - Wed Apr 29, 11:47AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce that its current lead compound APC 101 successfully diminished the frequency of tumor metastasis in the 4T1 animal model. APC.VN: 0.040 (-0.010)
Advanced Proteome Therapeutics Reports Successful Fusion Protein Initiative Resulting in APC 103 Which Retards Tumor Growth in an Animal Model
Marketwired - Mon Apr 27, 8:02AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce that its new fusion protein, APC 103, exhibited enhanced activity over the parent protein in retarding tumor growth in animal studies, comparable to APC 101 which has been the Company's principal point of focus to date. APC.VN: 0.040 (-0.010)
